B. Nixon

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis.

B. Blumenstein, G. Selvaggi, U. Wiedermann, 2023, Journal of Clinical Oncology.

Phase I study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer.

J. Waisman, S. Chaurasiya, J. Mortimer, 2022, Journal of Clinical Oncology.

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)

Z. Andrić, E. Garner-Spitzer, N. Ede, 2024, Clinical Cancer Research.

nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.

T. Price, G. Selvaggi, N. Withana, 2023, Journal of Clinical Oncology.